MDIPID: Microbiota‐drug interaction and disease phenotype interrelation database
Open Access
Abstract
The intricate bidirectional relationships among microbiota, microbial proteins, drugs, and diseases are essential for advancing precision medicine and minimizing adverse drug reactions. However, there are currently no data resources that comprehensively describe these valuable interactions. Therefore, the Microbiota-Drug Interaction and Disease Phenotype Interrelation Database (MDIPID) database was developed in this study. MDIPID is distinctive in its ability to elucidate the complex interactions among microbiota, microbial proteins, drugs/substances, and disease phenotypes, thereby providing a comprehensive interconnected network that facilitates the identification of microbial therapy targets and advances personalized medicine. This comprehensive resource is expected to become a popular repository for researchers aiming to identify microbial therapeutic targets, predict drug efficacy, and develop new therapies, thereby facilitating the advancement of personalized medicine. MDIPID can be accessed free without any login requirement at: https://idrblab.org/mdipid/.Keywords
Funding Information
- National Natural Science Foundation of China (32400516)
This publication has 20 references indexed in Scilit:
- Utilization of the microbiome in personalized medicineNature Reviews Microbiology, 2023
- From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human healthAutoimmunity Reviews, 2023
- Drug-microbiota interactions: an emerging priority for precision medicineSignal Transduction and Targeted Therapy, 2023
- High-resolution analyses of associations between medications, microbiome, and mortality in cancer patientsCell, 2023
- Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applicationsSignal Transduction and Targeted Therapy, 2023
- The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assemblyThe Lancet Microbe, 2022
- Human gut bacterial β-glucuronidase inhibition: An emerging approach to manage medication therapyBiochemical Pharmacology, 2021
- Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?Clinical Pharmacology & Therapeutics, 2019
- Malassezia Is Associated with Crohn’s Disease and Exacerbates Colitis in Mouse ModelsCell Host & Microbe, 2019
- In vitro fermentation of fructooligosaccharides with human gut bacteriaFood & Function, 2015